Classification, Labelling and Packaging Regulation

02008R1272-20250201 → 02008R1272-20250901

compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere

ANNEX VI Harmonised classification and labelling for certain hazardous substances Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3. … 908 unchanged lines … Wng H302 H335 H317 H410 006-015-00-9 diuron (ISO); 3-(3,4-dichlorophenyl)-1,1-dimethylurea 206-354-4 330-54-1 Carc. 2 Acute Tox. 4 * STOT RE 2 * H410 006-015-00-9 diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea 206-354-4 330-54-1 Carc. 1B STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H373** Aquatic Chronic 1 H350 H373 (blood system) H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H373** H410 M = 10 006-016-00-4 propoxur (ISO); Dgr H350 H373 (blood system) H410 M = 100 M = 100 006-016-00-4 propoxur (ISO); 2-isopropyloxyphenyl N-methylcarbamate; 2-isopropoxyphenyl methylcarbamate 204-043-8 114-26-1 Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 H301 … 3,671 unchanged lines … H410 GHS07 GHS09 Wng H317 H410 015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. 2 H361f (causing atrophy of the testes) GHS08 Wng H361f (causing atrophy of the testes) 016-001-00-4 hydrogen sulphide 231-977-3 7783-06-4 Flam. Gas 1 H410 015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. 1B Skin Sens. 1B H360Fd H317 GHS08 GHS07 Dgr H360Fd H317 015-204-00-5 benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate 479-100-5 577705-90-9 Repr. 1B H360F GHS08 Dgr H360F 015-205-00-0 benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) 278-305-5 75768-65-9 Repr. 1B H360F GHS08 Dgr H360F 015-206-00-6 reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) — — Repr. 1B H360F GHS08 Dgr H360F 015-207-00-1 reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1) — — Repr. 1B H360F GHS08 Dgr H360F 015-208-00-7 dimethyl propylphosphonate 242-555-3 18755-43-6 Muta. 1B Repr. 1B H340 H360Df GHS08 Dgr H340 H360Df 016-001-00-4 hydrogen sulphide, hydrogen sulfide 231-977-3 7783-06-4 Flam. Gas 1A Press. Gas Acute Tox. 2 * Acute Tox. 2 Aquatic Acute 1 H220 H330 H400 GHS02 GHS04 GHS06 GHS09 Dgr H220 H330 H400 U H400 inhalation: ATE = 440 ppmV (gases) U 016-002-00-X barium sulphide 244-214-4 21109-95-5 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 H332 … 73 unchanged lines … GHS09 Dgr H301 H314 H400 EUH031 016-011-00-9 sulphur dioxide 231-195-2 7446-09-5 Press. Gas Acute Tox. 3 * Skin Corr. 1B H331 H400 EUH031 016-011-00-9 sulphur dioxide; sulfur dioxide 231-195-2 7446-09-5 Press. Gas Acute Tox. 3 STOT SE 1 Skin. Corr. 1B H331 H370 (respiratory system) (inhalation) H314 GHS04 GHS06 GHS08 GHS05 Dgr H331 H314 * U5 H370 (respiratory system) (inhalation) H314 inhalation: ATE = 1000 ppmV (gases) U, 5 016-012-00-4 disulphur dichloride; sulfur monochloride 233-036-2 10025-67-9 Acute Tox. 3 * Acute Tox. 4 * … 621 unchanged lines … H332 H302 H411 017-004-00-3 potassium chlorate 223-289-7 3811-04-9 Ox. Sol. 1 Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 H271 H332 H302 H411 GHS03 GHS07 GHS09 Acute Tox. 3 H271 H301 GHS03 GHS06 Dgr H271 H332 H302 H411 017-005-00-9 sodium chlorate 231-887-4 7775-09-9 Ox. Sol. 1 Acute Tox. 4 * Aquatic Chronic 2 H271 H302 H411 GHS03 GHS07 GHS09 H301 oral: ATE = 100 mg/kg bw 017-005-00-9 sodium chlorate 231-887-4 7775-09-9 Ox. Sol. 1 Acute Tox. 3 H271 H301 GHS03 GHS06 Dgr H271 H302 H411 017-006-00-4 perchloric acid … % 231-512-4 7601-90-3 Ox. Liq. 1 H301 oral: ATE = 100 mg/kg bw 017-006-00-4 perchloric acid … % 231-512-4 7601-90-3 Ox. Liq. 1 Skin Corr. 1A H271 H314 GHS03 GHS05 … 3,476 unchanged lines … H372 (immune system) GHS08 Dgr H341 H360FD H372 (immune system) 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B H372 (immune system) 050-034-00-5 dibutyltin maleate 201-077-5 78-04-6 Muta. 2 Repr. 1B Acute Tox. 2 Acute Tox. 4 STOT RE 1 Skin Corr. 1 Eye Dam. 1 H341 H360FD H330 H302 H372 (immune system) H314 H318 GHS08 GHS06 GHS05 Dgr H341 H360FD H330 H302 H372 (immune system) H314 inhalation: ATE = 0,317 mg/L (dusts or mists) oral: ATE = 510 mg/kg bw 050-035-00-0 dibutyltin oxide 212-449-1 818-08-6 Muta. 2 Repr. 1B Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 H341 H360FD H301 H372 (immune system) H315 H318 GHS08 GHS06 GHS05 Dgr H341 H360FD H301 H372 (immune system) H315 H318 oral: ATE = 170 mg/kg bw 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B Aquatic Chronic 2 H314 H411 GHS05 GHS09 … 787 unchanged lines … GHS09 Wng H302 H373** H411 082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A H411 082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 H360FD H362 H400 H410 GHS08 GHS09 Dgr H360FD H362 H410 Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10 082-014-00-7 lead massive: [particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. H360FD H362 GHS08 Dgr H360FD H362 092-001-00-8 uranium 231-170-6 7440-61-1 Acute Tox. 2 * H362 H410 Repr. 1A; H360D: C ≥ 0,03 % M = 10 M = 100 082-014-00-7 lead massive: [particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. Aquatic Chronic 1 H360FD H362 H410 GHS08 GHS09 Dgr H360FD H362 H410 M = 10 092-001-00-8 uranium 231-170-6 7440-61-1 Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 4 H330 … 3,002 unchanged lines … H315 H317 H411 C 603-057-00-5 benzyl alcohol 202-859-9 100-51-6 Acute Tox. 4 * Acute Tox. 4 * H332 H302 GHS07 Wng H332 H302 603-058-00-0 1,3-propylene oxide 207-964-3 503-30-0 Flam. Liq. 2 603-057-00-5 benzyl alcohol 202-859-9 100-51-6 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1B H302 H319 H317 GHS07 Wng H302 H319 H317 oral: ATE = 1200 mg/kg bw 603-058-00-0 1,3-propylene oxide 207-964-3 503-30-0 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * H225 H332 H312 … 1,137 unchanged lines … Muta. 2 H350 H341 GHS08 Dgr H350 H341 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 H341 603-244-00-1 reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane — — Muta. 2 Repr. 1B H341 H360F GHS08 Dgr H341 H360F 603-245-00-7 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol 221-665-5 3179-89-3 Skin Sens. 1 H317 GHS07 Wng H317 603-246-00-2 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol 211-477-1 647-42-7 STOT RE 2 Aquatic Chronic 1 H373 (teeth, bones) H410 GHS08 GHS09 Wng H373 (teeth, bones) H410 M = 1 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B H341 … 158 unchanged lines … H332 H312 H302 H412 * 604-010-00-1 resorcinol; 1,3-benzenediol 203-585-2 108-46-3 Acute Tox. 4 * H412 * 604-010-00-1 resorcinol; 1,3-benzenediol 203-585-2 108-46-3 Acute Tox. 4 STOT SE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1B Aquatic Acute 1 H302 H370 (nervous system) H315 H319 H317 H400 GHS07 GHS08 GHS09 Dgr H302 H370 (nervous system) H315 H400 GHS07 GHS09 Wng H302 H319 H315 H400 * 604-011-00-7 2,4-dichlorophenol 204-429-6 120-83-2 Acute Tox. 3 * H317 H400 oral: ATE = 500 mg/kg bw M = 1 604-011-00-7 2,4-dichlorophenol 204-429-6 120-83-2 Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 H311 … 455 unchanged lines … GHS09 Dgr H351 H360F*** H317 H410 604-074-00-0 tetrabromobisphenol-A; 2,2', 6,6'-tetrabromo-4,4'-isopropylidenediphenol 201-236-9 79-94-7 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 604-075-00-6 4-(1,1,3,3-tetramethylbutyl)phenol; 4-tert-octylphenol 205-426-2 140-66-9 Skin Irrit. 2 H410 604-074-00-0 2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A 201-236-9 79-94-7 Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 H350 H400 H410 GHS08 GHS09 Dgr H350 H410 604-075-00-6 4-(1,1,3,3-tetramethylbutyl)phenol; 4-tert-octylphenol 205-426-2 140-66-9 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H315 … 188 unchanged lines … H373 (liver) H317 oral: ATE = 500 mg/kg bw 604-098-00-1 4,4'-sulphonyldiphenol; bisphenol S 201-250-5 80-09-1 Repr. 1B H360FD GHS08 Dgr H360FD 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Dgr H360FD 604-099-00-7 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF 216-036-7 1478-61-1 Repr. 1B H360F GHS08 Dgr H360F 604-100-00-0 nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] 500-315-8 500-024-6 500-045-0 500-209-1 248-762-5 243-816-4 248-291-5 — 230-770-5 248-743-1 247-555-7 248-293-6 — and others 127087-87-0 9016-45-9 26027-38-3 68412-54-4 27986-36-3 20427-84-3 27176-93-8 1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 10 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1 H350 … 603 unchanged lines … H302 H319 H315 H411 606-034-00-8 metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one 244-209-7 21087-64-9 Acute Tox. 4 * Aquatic Acute 1 H411 606-034-00-8 metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one 244-209-7 21087-64-9 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (blood system) H400 H410 GHS07 GHS08 GHS09 Wng H302 H410 M=10 606-035-00-3 chloridazon (ISO); 5-amino-4-chloro-2-phenylpyridazine-3-(2H)-one; pyrazon 216-920-2 1698-60-8 Skin Sens. 1 H373 (blood system) H410 oral: ATE = 320 mg/kg bw M = 10 M = 10 606-035-00-3 chloridazon (ISO); 5-amino-4-chloro-2-phenylpyridazine-3-(2H)-one; pyrazon 216-920-2 1698-60-8 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 … 584 unchanged lines … H410 oral: ATE = 500 mg/kg bw M = 10 M = 10 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 M = 10 606-155-00-6 cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2E)-3-phenylprop-2-enal [2] 203-213-9 [1] - [2] 104-55-2 [1] 14371-10-9 [2] Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % … 253 unchanged lines … H332 607-031-00-4 butyl butyrate 203-656-8 109-21-7 Flam. Liq. 3 H226 GHS02 Wng H226 C 607-032-00-X ethyl acrylate 205-438-8 140-88-5 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H225 H332 H331 H312 H302 H319 H335 H315 H319 H317 GHS02 GHS07 GHS06 Dgr H225 H332 H331 H312 H302 H319 H335 H315 H317 Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % STOT SE 3; H335: C ≥ 5 % D H319 H317 inhalation: ATE = 9 mg/L (vapours) dermal: ATE = 1800 mg/kg bw oral: ATE = 1120 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % D 607-033-00-5 n-butyl methacrylate 202-615-1 97-88-1 Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 H226 H319 H335 H315 H317 GHS02 GHS07 Wng H226 H319 H335 H315 H317 D 607-034-00-0 methyl acrylate; methyl propenoate 202-500-6 96-33-3 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 607-034-00-0 methyl acrylate; methyl propenoate 202-500-6 96-33-3 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H225 H332 H331 H312 H302 H319 H335 H315 H319 H317 GHS02 GHS07 GHS06 Dgr H225 H332 H331 H312 H302 H319 H335 H315 H317 D H319 H317 inhalation: ATE = 3 mg/L (vapours) dermal: ATE = 1100 mg/kg bw oral: ATE = 500 mg/kg bw D 607-035-00-6 methyl methacrylate; methyl 2-methylprop-2-enoate; methyl 2-methylpropenoate 201-297-1 80-62-6 Flam. Liq. 2 STOT SE 3 Skin Irrit. 2 … 1,546 unchanged lines … H411 GHS07 GHS09 Wng H317 H411 607-223-00-8 transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl trans-2-(2,2-dichlorovinyl)-3,3-dimethylcyclopropanecarboxylate 405-060-5 118712-89-3 Skin Irrit. 2 H411 607-223-00-8 transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 405-060-5 118712-89-3 Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H315 Aquatic Chronic 1 H351 H302 H370 (nervous system) H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H315 H410 607-224-00-3 methyl 2-(3-nitrobenzylidene)acetoacetate 405-270-7 39562-17-9 Skin Sens. 1 Wng H351 H302 H370 (nervous system) H410 EUH066 oral: ATE = 580 mg/kg bw M = 1000 M = 1000 607-224-00-3 methyl 2-(3-nitrobenzylidene)acetoacetate 405-270-7 39562-17-9 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 … 202 unchanged lines … H315 H317 H411 D 607-246-00-3 allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester 202-473-0 96-05-9 Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 H226 H331 H312 607-246-00-3 allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester 202-473-0 96-05-9 Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 H226 H330 H311 H302 H400 GHS02 GHS06 GHS09 Dgr H226 H331 H312 H330 H311 H302 H400 607-247-00-9 dodecyl methacrylate 205-570-6 142-90-5 STOT SE 3 H335 GHS07 H400 inhalation: ATE = 1,5 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 400 mg/kg bw 607-247-00-9 dodecyl methacrylate 205-570-6 142-90-5 STOT SE 3 H335 GHS07 Wng H335 STOT SE 3; H335: C ≥ 10 % 607-248-00-4 naptalam-sodium (ISO); sodium N-naphth-1-ylphthalamate 205-073-4 132-67-2 Acute Tox. 4 * H302 GHS07 Wng H302 607-249-00-X (1-methyl-1,2-ethanediyl)bis[oxy(methyl-2,1-ethanediyl)] diacrylate 256-032-2 42978-66-5 Eye Irrit. 2 STOT SE 3 … 2,769 unchanged lines … GHS07 Dgr H360FD H319 607-765-00-5 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid — — Repr. 1B H360FD GHS08 Dgr H360FD 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Dgr H360FD 607-766-00-0 tetramethylene dimethacrylate 218-218-1 2082-81-7 Skin Sens. 1B H317 GHS07 Wng H317 607-767-00-6 7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate 276-957-5 72869-86-4 Skin Sens. 1B H317 GHS07 Wng H317 607-768-00-1 2,2'-ethylenedioxydiethyl dimethacrylate 203-652-6 109-16-0 Skin Sens. 1B H317 GHS07 Wng H317 607-769-00-7 bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate 255-894-7 42576-02-3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 1500 mg/kg bw M = 1000 M = 1000 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 H225 H332 … 2,640 unchanged lines … H312 H302 H314 STOT SE 3; H335: C ≥ 1 % 612-004-00-5 triethylamine 204-469-4 121-44-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A H225 H332 H312 H302 H314 GHS02 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1A Eye Dam. 1 H225 H331 H311 H301 H314 H318 GHS02 GHS06 GHS05 GHS07 Dgr H225 H332 H312 H302 H314 STOT SE 3; H335: C ≥ 1 % 612-005-00-0 butylamine 203-699-2 109-73-9 Flam. Liq. 2 H331 H311 H301 H314 inhalation: ATE = 7,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 % 612-005-00-0 butylamine 203-699-2 109-73-9 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * … 624 unchanged lines … H332 H312 H302 H314 STOT SE 3; H335: C ≥ 1 % 612-049-00-0 di-n-butylamine; [1] di-sec-butylamine [2] 203-921-8 [1] 210-937-9 [2] 111-92-2 [1] 626-23-3 [2] Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * H226 H332 H312 H302 GHS02 GHS07 Wng H226 H332 H312 H302 612-050-00-6 cyclohexylamine 203-629-0 108-91-8 Flam. Liq. 3 H314 STOT SE 3; H335: C ≥ 1 % 612-049-00-0 di-n-butylamine 203-921-8 111-92-2 Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 H226 H330 H311 H301 H314 H318 GHS02 GHS06 GHS05 Dgr H226 H330 H311 H301 H314 EUH 071 inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 220 mg/kg bw 612-050-00-6 cyclohexylamine 203-629-0 108-91-8 Flam. Liq. 3 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * … 98 unchanged lines … H301 H373 ** H412 C 612-056-00-9 N,N-dimethyl-p-toluidine; [1] N,N-dimethyl-m-toluidine; [2] N,N-dimethyl-o-toluidine [3] 202-805-4 [1] 204-495-6 [2] 210-199-8 [3] 99-97-8 [1] 121-72-2 [2] 609-72-3 [3] Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 H331 612-056-00-9 N,N-dimethyl-m-toluidine; [1] N,N-dimethyl-o-toluidine [2] 204-495-6 [1] 210-199-8 [2] 121-72-2 [1] 609-72-3 [2] Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 H331 H311 H301 H373 ** H412 GHS06 GHS08 H412 GHS06 GHS08 Dgr H331 H311 H301 … 2,701 unchanged lines … GHS09 Dgr H314 H410 EUH071 M = 100 M = 1000 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 M = 1000 612-295-00-9 benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine 217-465-2 1861-40-1 Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H361d H315 H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361d H315 H319 H317 H410 M = 10 M = 10 612-296-00-4 N,N-dimethyl-p-toluidine 202-805-4 99-97-8 Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 H350 H332 H301 H373 (blood system, respiratory tract) H412 GHS08 GHS06 Dgr H350 H332 H301 H373 (blood system, respiratory tract) H412 inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 140 mg/kg bw 612-297-00-X 1-phenylethan-1-one (1-phenylethylidene)hydrazone 211-979-0 729-43-1 Skin Sens. 1 H317 GHS07 Wng H317 612-298-00-5 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; 273-227-8 68953-84-4 Repr. 1B Skin Sens. 1 H360FD H317 GHS08 GHS07 Dgr H360FD H317 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 Carc. 1B Muta. 1B Acute Tox. 2 * … 875 unchanged lines … H302 H319 H315 H412 613-088-00-6 1,2-benzisothiazol-3(2H)-one;1,2-benzisothiazolin-3-one 220-120-9 2634-33-5 Acute Tox. 4 * H412 613-088-00-6 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one 220-120-9 2634-33-5 Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 H302 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H315 H318 H317 H400 GHS05 GHS07 H400 H410 GHS06 GHS05 GHS09 Dgr H302 Dgr H330 H302 H315 H318 H317 H400 Skin Sens. 1; H317: C≥0,05 % 613-089-00-1 diquat dibromide; [1]diquat dichloride; [2]6,7-dihydrodipyrido[1,2-α:2',1'- c]pyrazinediylium dihydroxide [3] 201-579-4 [1] H410 inhalation: ATE = 0,21 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,036 % M = 1 M = 1 613-089-00-1 diquat dibromide; [1]diquat dichloride; [2]6,7-dihydrodipyrido[1,2-α:2',1'- c]pyrazinediylium dihydroxide [3] 201-579-4 [1] 223-714-6 [2] 301-467-6 [3] 85-00-7 [1] 4032-26-2 [2] … 321 unchanged lines … Aquatic Chronic 3 H319 H412 GHS07 Wng H319 H412 613-127-00-7 1,1-dimethylpiperidinium chloride; mepiquat chloride 246-147-6 24307-26-4 Acute Tox. 4 * Aquatic Chronic 3 H302 H412 GHS07 Wng H302 H412 613-128-00-2 prochloraz (ISO);N-propyl-N-[2-(2,4,6-trichlorop henoxy)ethyl]-1H-imidazole-1- carboxamide 266-994-5 67747-09-5 Acute Tox. 4 * Aquatic Acute 1 H412 613-127-00-7 mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride 246-147-6 24307-26-4 Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 H332 H301 H412 GHS06 Dgr H332 H301 H412 inhalation: ATE = 2,8 mg/L (dusts or mists) oral: ATE = 270 mg/kg bw 613-128-00-2 prochloraz (ISO);N-propyl-N-[2-(2,4,6-trichlorop henoxy)ethyl]-1H-imidazole-1- carboxamide 266-994-5 67747-09-5 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 … 1,218 unchanged lines … GHS09 Wng H302 H317 H411 613-307-00-5 clothianidin (ISO); 3-[(2-chloro-1,3-thiazol-5-yl)methyl]-2-methyl-1-nitroguanidine — 210880-92-5 Acute Tox. 4 * H411 613-307-00-5 clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine 433-460-1 210880-92-5 Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H302 Aquatic Chronic 1 H361f H302 H370 (nervous system) H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H302 H410 M=10 613-308-00-0 2-amino-5-methylthiazole 423-800-5 7305-71-7 Acute Tox. 4 * Dgr H361f H302 H370 (nervous system) H410 oral: ATE = 390 mg/kg bw M = 10 M = 100 613-308-00-0 2-amino-5-methylthiazole 423-800-5 7305-71-7 Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 H302 … 439 unchanged lines … STOT RE 2 H351 H373 (urinary tract) GHS08 Wng H351 H373 (urinary tract) 614-001-00-4 nicotine (ISO); H373 (urinary tract) 613-346-00-8 4-nitrosomorpholine — 59-89-2 Carc. 1B Muta. 2 STOT RE 1 H350 H341 H372 (liver) GHS08 Dgr H350 H341 H372 (liver) Carc. 1B; H350: C ≥ 0,001 % 613-347-00-3 difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether — 119446-68-3 Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H319 H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H319 H410 oral: ATE = 1450 mg/kg bw M = 10 M = 10 613-348-00-9 9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 213-584-9 989-38-8 Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H301 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H301 H318 H317 H410 oral: ATE = 280 mg/kg bw M = 10 M = 1 613-349-00-4 4-methylimidazole 212-497-3 822-36-6 Carc. 1B Repr. 1B H350 H360Fd GHS08 Dgr H350 H360Fd 614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 … 786 unchanged lines … H334 H317 H412 inhalation: ATE = 0,27 mg/L (dusts or mists) 616-001-00-X N, N-dimethylformamide; ATE = 0,27 mg/L (dusts or mists) 615-051-00-X 3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate 202-112-7 91-97-4 Carc. 2 Resp. Sens. 1 Skin Sens. 1A H351 H334 H317 GHS08 Dgr H351 H334 H317 Skin Sens. 1A; H317: C ≥ 0,001 % 616-001-00-X N, N-dimethylformamide; dimethyl formamide 200-679-5 68-12-2 Repr. 1B Acute Tox. 4 * Acute Tox. 4 * … 269 unchanged lines … Dgr H301 H312 H410 616-034-00-X pyracarbolid; (ISO); 3,4-dihydro-6-methyl-2H-pyran-5-carboxanilide 246-419-4 24691-76-7 Aquatic Chronic 3 H412 — H412 616-035-00-5 cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide 261-043-0 57966-95-7 Repr. 2 3,4-dihydro-6-methyl-2H-pyran-5-carboxanilide 246-419-4 24691-76-7 Aquatic Chronic 3 H412 — H412 616-035-00-5 cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1] (2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2] 261-043-0 [1] - [2] 57966-95-7 [1] 166900-80-7 [2] Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361fd H302 H373 (blood, thymus) H373 (blood system, thymus, eyes) H317 H400 H410 GHS08 GHS07 GHS09 Wng H361fd H302 H373 (blood, thymus) H373 (blood system, thymus, eyes) H317 H410 M = 1 M = 1 616-036-00-0 2-chloracetamide 201-174-2 79-07-2 Repr. 2 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1 616-036-00-0 2-chloracetamide 201-174-2 79-07-2 Repr. 2 Acute Tox. 3 * Skin Sens. 1 H361f *** H301 H317 GHS06 … 287 unchanged lines … H410 GHS07 GHS09 Wng H317 H410 616-104-00-X benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate 275-728-7 71626-11-4 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 616-105-00-5 chlorotoluron (ISO); H410 616-104-00-X benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate 275-728-7 71626-11-4 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 1000 mg/kg bw M = 1 M = 1 616-105-00-5 chlorotoluron (ISO); 3-(3-chloro-p-tolyl)-1,1-dimethylurea 239-592-2 15545-48-9 Carc. 2 Repr. 2 Aquatic Acute 1 … 687 unchanged lines … GHS09 Dgr H351 H360D H317 H410 Repr. 1B; H360D: H317H410 Repr. 1B; H360D: C ≥ 3 % M = 10 M = 10 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 M = 10 616-241-00-5 foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea — 173159-57-4 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 1000 M = 100 616-242-00-0 picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide — 137641-05-5 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H373 (blood system, thyroid) H400 H410 GHS08 GHS09 Wng H373 (blood system, thyroid) H410 M = 1000 M = 1000 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 H341 GHS02 GHS08 … 24,970 unchanged lines … S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N R: 50/53 S: 60-61